Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02281136 · ClinicalTrials.gov registry record · Phase 2
Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
A Phase 2 study, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02281136 is a Phase 2 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT02281136, a Phase 2 study, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
Interventions
- DRUG Aminolevulinic Acid (ALA)
- DEVICE BLU-U
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02281136
The ClinicalTrials.gov registry entry for NCT02281136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DUSA Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aminolevulinic Acid (ALA) is the first listed.
NCT02281136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02281136 about?
NCT02281136 is a clinical study titled "Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick". The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
What is the current status of trial NCT02281136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2014-12. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02281136?
The interventions under investigation include: Aminolevulinic Acid (ALA) (DRUG), BLU-U (DEVICE).
Who is sponsoring clinical trial NCT02281136?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.